NUVL
Nuvalent, Inc.
NASDAQ · USHealthcareBiotechnology
$123.96+0.00%
Price as of Jul 14, 2026
NUVL financials
Nuvalent, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $414.3M | $280.4M | $149.5M | $86.1M |
| Operating income | -$414.3M | -$280.4M | -$149.5M | -$86.1M |
| Net income | -$425.4M | -$260.8M | -$126.2M | -$81.9M |
| EBITDA | -$10.5M | $20.4M | -$126.2M | -$81.9M |
| Basic EPS | $-5.85 | $-3.93 | $-2.17 | $-1.65 |
| Diluted EPS | $-5.85 | $-3.93 | $-2.17 | $-1.65 |
| Balance sheet | ||||
| Cash & equivalents | $261.7M | $145.7M | $335.4M | $241.8M |
| Total assets | $1.4B | $1.1B | $732.4M | $482.5M |
| Total liabilities | $164.4M | $72.0M | $31.8M | $19.5M |
| Stockholders’ equity | $1.2B | $1.1B | $700.6M | $463.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Net debt | -$261.7M | -$145.7M | -$335.4M | -$241.8M |
| Cash flow | ||||
| Operating cash flow | -$275.2M | -$185.1M | -$99.7M | -$65.0M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$275.2M | -$185.1M | -$99.7M | -$65.0M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |